Nadja West
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Tempus AI Expands Collaborations, Canaccord Raises Target to $95. Tempus AI is expanding its strategic collaborations to support future growth. Canaccord Genuity recently raised its price target for the stock to $95. This development occurs as the company prepares to report its third-quarter financial results on November 2.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Nucor Expands Indiana Pole Output Amid Tariff-Driven Steel Price Climb. Nucor is expanding its Indiana utility pole output and investing $105 million in higher-value grid steel, while US steel prices climb to four-year highs on tariff impacts. Recent tariff uncertainty has caused Nucor and its peers to slip, but the company's focus on grid infrastructure remains a key driver. Analysis suggests the stock trades below fair value following a significant run, as the market weighs policy-driven price trends against production expansion.
Transaction History
| THC | ▼ Sell | Open Market | 1,152 | $298K | 9/2/2026 | View on chart |
| TEM | ▼ Sell | Open Market | 3,000 | $207K | 8/28/2026 | View on chart |
| TEM | ▼ Sell | Open Market | 3,000 | $162K | 8/14/2026 | View on chart |
| NUE | ▲ Buy | Grant | 755 | $0 | 6/1/2026 | View on chart |
| THC | ▼ Sell | Open Market | 3,000 | $532K | 5/27/2026 | View on chart |
| THC | ▲ Buy | Option Exercise | 1,333 | — | 5/22/2026 | View on chart |
| THC | ▼ Sell | Other | 493 | $86K | 5/22/2026 | View on chart |
| TEM | ▲ Buy | Grant | 5,913 | $0 | 5/21/2026 | View on chart |
| THC | ▼ Sell | Gift | 1,515 | $0 | 2/17/2026 | View on chart |
| THC | ▼ Sell | Open Market | 2,178 | $430K | 12/15/2025 | View on chart |
| NUE | ▲ Buy | Grant | 1,554 | $0 | 6/1/2025 | View on chart |
| THC | ▲ Buy | Option Exercise | 1,551 | — | 5/23/2025 | View on chart |
| THC | ▼ Sell | Other | 573 | $92K | 5/23/2025 | View on chart |
| TEM | ▲ Buy | Grant | 1,997 | $0 | 5/20/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 1,900 | $91K | 3/17/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 700 | $35K | 3/17/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 2,789 | $140K | 3/17/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 760 | $37K | 3/17/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 1,485 | $69K | 3/17/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 249 | $13K | 3/4/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 200 | $10K | 3/4/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 120 | $6K | 3/4/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 160 | $9K | 3/4/2025 | View on chart |
| TEM | ▼ Sell | Open Market | 80 | $4K | 3/4/2025 | View on chart |
| TEM | ▲ Buy | Grant | 38,514 | $0 | 6/13/2024 | View on chart |
| NUE | ▲ Buy | Grant | 1,006 | $0 | 6/1/2024 | View on chart |
| THC | ▼ Sell | Open Market | 1,782 | $225K | 5/9/2024 | View on chart |
| NUE | ▲ Buy | Grant | 1,240 | $0 | 6/1/2023 | View on chart |
| THC | ▲ Buy | Grant | 2,846 | $0 | 5/26/2023 | View on chart |
| NUE | ▲ Buy | Grant | 1,262 | $0 | 6/1/2022 | View on chart |
| THC | ▲ Buy | Grant | 3,836 | $0 | 5/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Tenet Healthcare Raises 2026 Outlook, Analysts Lift Targets
Tenet Healthcare recently raised its 2026 financial outlook, prompting analysts like Guggenheim to increase price targets to $307. This positive guidance has driven the stock higher, with the average analyst target now sitting at $285.32. While the company is trading near its 52-week high, questions remain about whether this recent strength is fully reflected in the current valuation.
Tenet Healthcare Raises 2026 Outlook, Analysts Lift Targets. Tenet Healthcare recently raised its 2026 financial outlook, prompting analysts like Guggenheim to increase price targets to $307. This positive guidance has driven the stock higher, with the average analyst target now sitting at $285.32. While the company is trading near its 52-week high, questions remain about whether this recent strength is fully reflected in the current valuation.